Staff Report
ISLAMABAD: Pakistan is on the threshold of becoming the first country to carry out the research, mandatory to introduce intravenous immunoglobulin (C-IVIG) therapy at a mass level as ‘severe’ patients under treatment for coronavirus, have 100 percent recovery rate. This was pointed out by scientists at Karachi’s Dow University of Health Sciences (DUHS), who are conducting clinical trials of intravenous immunoglobulin (C-IVIG) therapy for the treatment coronavirus. The therapy uses immunoglobulin (IG), a blood product extracted from the plasma of people who have recovered from infection, and which is rich in the antibodies that target the virus. Continuous infusion of immunoglobin can neutralize the infection in patients and shorten the course of the disease, scientists at DUHS said.
In June, DUHS trials started on 30 participants, most from the high-risk group of people above the age of 60, with many suffering from diabetes, hypertension and other comorbidities.
“The trials are very encouraging and remarkable,” Dr. Shaukat Ali, head of biotechnology at DUHS and lead on the C-IVIG project, said in an interview. “At the moment, what we have seen is that all severe patients who received C-IVIG treatment had 100 percent recovery ratio while in critical patients the recovery ratio was 50 to 60 percent.” Besides, the high recovery rate, Dr. Ali said, the DUHS team had observed that the treatment had significantly reduced the period of hospitalization.
